Drug reference
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with insulin or Endocrine system other antidiabetic drugs ▶BY MOUTH ▶Adult: 1 tablet twice daily, dose based on patient’s current metformin dose, daily dose of metformin should not exceed 2 g
PDF page 764
DUE TO INTERACTIONS ▶Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.
PDF page 764
Scottish Medicines Consortium (SMC) decisions SMC No. 1019/14 The Scottish Medicines Consortium has advised (January 2015) that canagliflozin with metformin (Vokanamet ®) is accepted for restricted use within NHS Scotland in patients with type 2 diabetes mellitus for whom a combination of canagliflozin and metformin is an appropriate choice of therapy.
PDF page 764
→Appendix 1: canagliflozin. metformin
PDF page 764
Avoid if eGFR less than 60 mL/minute/1.73 m2.
PDF page 764
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Vokanamet (Napp Pharmaceuticals Ltd) Canagliflozin (as Canagliflozin hemihydrate) 50 mg, Metformin hydrochloride 850 mg Vokanamet 50mg/850mg tablets | 60 tablet P £39.20 DT = £39.20 Canagliflozin (as Canagliflozin hemihydrate) 50 mg, Metformin hydrochloride 1 gram Vokanamet 50mg/1000mg tablets | 60 tablet P £39.20 DT = £39.20
PDF page 764
1 tablet twice daily, dose based on patient’s
First-line fragment. Read the complete Indications and Dose section above.
PDF page 764
